Plain-English translation of NCT07136701 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers want to understand why pancreatic neuroendocrine tumors (rare tumors of the pancreas) behave differently depending on whether someone is diagnosed before or after age 50. By comparing medical records, pathology reports, and follow-up information from patients treated at multiple hospitals, the study team hopes to discover whether younger and older patients have different tumor characteristics, survival rates, and associated health conditions.
Pancreatic neuroendocrine tumors are rare, and doctors don't yet fully understand whether age at diagnosis affects how aggressive the tumor is, how well patients recover, or what their long-term outlook looks like. This study exists to fill that gap so doctors can better predict outcomes and tailor treatment for patients of different ages.
You likely qualify if…
You likely don't qualify if…
You will not attend clinic visits or take any new medication. Instead, researchers will review your existing medical records, pathology reports, and imaging results already on file at your hospital. The study team will track your health outcomes and any tumor recurrence through follow-up data in your records. Your participation is purely observational—researchers are simply gathering information to compare patients diagnosed at different ages.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China